TESARO (TSRO) shares surged more than 100% on Wednesday after the company positive results from a Phase 3 clinical trial, NOVA, evaluating its PARP inhibitor niraparib in women with ovarian cancer, including those who are germline BRCA mutation carriers and those who are not germline BRCA carriers but who have homologous recombination deficient (HRD) tumors [as determined by Myriad Genetics' (NASDAQ:MYGN) myChoice HRD test]. TSRO closed at $77.40 on Wednesday. Following the positive results, FBR & Co. raised their price target on TSRO to $93. FBR’s price target still implies an upside of 20% from current levels.